← Back to list
Patient Capital ManagementArticle17 Aug 2026Source: patientcapitalmanagement.com

Opportunity Equity Strategy Update for 8/07/2026 – 8/14/2026

Patient Capital Management is a Baltimore asset manager founded in 2020 by Samantha McLemore, CFA — Bill Miller's long-time co-manager (working together since 2002, running the flagship Opportunity Equity strategy since 2014). Continuing the Miller-school contrarian tradition, it practices "time arbitrage": exploiting behavioral mispricing to concentrate in controversial growth names (tech, healthcare, Bitcoin-related) at deep discounts to intrinsic value. Its site preserves Bill Miller's complete 1995-2022 market letters, alongside ongoing quarterly letters and webinars.

Samantha McLemore · 2020 · 美国巴尔的摩Contrarian growth-value / time arbitrage

In plain words

This report covers Patient Capital's fund performance for the week of August 7-14. The fund fell 1.28%, lagging the S&P 500's 0.39% gain. The manager's view is that the market is very picky: companies that beat earnings and raise guidance get rewarded (e.g., Seadrill up 11%), while those that merely meet expectations get punished (e.g., QXO down 10%). Key holdings mentioned: Seadrill (beat estimates, raised guidance, stock up), Adyen (revenue beat, Goldman Sachs raised price target, stock up 14%), and Precigen (no positive news, stock down 15%).

AI SummaryAI-generated · may contain errors · verify against the original

Patient Capital’s Opportunity Equity strategy fell 1.28% last week (as of August 14, 2026), underperforming the S&P 500’s 0.39% gain, but remains up 17.04% year-to-date, leading the S&P 500 by approximately 250 basis points. The report highlights the performance and market reactions of several portf

~6 min full read · 5 sections
Deep Analysis

Monthly Scorecard

Month: -1.28% vs S&P 500 +0.39%, Year-to-Date: +17.04% vs +14.54%.

Metric Fund Benchmark (S&P 500)
Last Week (08/07-08/14) -1.28% +0.39%
Month-to-Date +3.94% +4.00%
Quarter-to-Date +6.19% +3.93%
Year-to-Date +17.04% +14.54%
1 Year +33.10% +21.81%
3 Years +27.81% +21.75%
5 Years +8.15% +13.36%
10 Years +14.20% +15.46%
Since Inception (Annualized, since 2000/6/26) +8.92% +8.61%

Who Contributed, Who Detracted

Contributors:

Position Type Weekly Net Return
Chime Financial Inc (CHYM) Stock +10.0%
Adyen N.V. (ADYEN NA) Stock +14.4%
Seadrill Limited (SDRL) Stock +11.0%
Royalty Pharma plc (RPRX) Stock +3.6%
Global Payments Inc. (GPN) Stock +8.0%

Detractors:

Position Type Weekly Net Return
Precigen, Inc. Warrants 2034 Derivative -17.6%
Precigen, Inc. (PGEN) Stock -15.6%
QXO, Inc. (QXO) Stock -10.2%
Amazon.com, Inc. (AMZN) Stock -4.3%
Broadcom Inc. (AVGO) Stock -8.1%

Individual Stock Commentary

  • Seadrill Limited (SDRL): Earnings beat expectations and guidance was raised, driving the stock up 11%. Revenue was $449 million (vs. $389 million expected), and EPS was $0.47 (vs. $0.35 expected). The company raised its FY26 revenue guidance by 5% and EBITDA guidance by 10% (both at the midpoint). A new one-year contract was signed at a day rate of $441,000, along with two contract extensions. Barclays maintained its price target of $59 (implying 23% upside). The author uses this case to illustrate the market's positive feedback to a "beat-and-raise."
  • Adyen N.V. (ADYEN NA): Net revenue beat expectations, Goldman Sachs significantly raised its price target, and the stock rose 14.4%. Net revenue was €682 million (up 22% YoY), above the expected €673 million; EPS was €17.18 vs. the expected €16.90. Goldman Sachs raised its price target from €1,800 to €1,850 (implying 74% upside), citing reasons including wallet share growth, new product launches, and the long-term potential of agentic commerce.
  • Chime Financial Inc (CHYM): Hit a 52-week high. Evercore raised its price target from $35 to $39 (implying 22% upside).
  • Royalty Pharma plc (RPRX): UBS raised its price target, citing improved internal rate of return. The target was raised from $58 to $66 (implying 13% upside), arguing that the company is shifting its royalty portfolio toward development-stage assets, improving the IRR; UBS also sees room for valuation multiple expansion, referencing that energy and gold royalty operators trade at a premium to their underlying operators.
  • Global Payments Inc. (GPN): Hit a 52-week high. Results from the prior week were broadly in line with expectations. Cantor Fitzgerald raised its price target from $76 to $91 (implying 2% downside), maintaining a neutral rating.
  • QXO, Inc. (QXO): Results were in line with expectations, but the stock broke below its 50-day moving average, falling 10.2%. Revenue was $3.246 billion (vs. $3.18 billion expected), EBITDA was $272 million (vs. $253 million expected), and adjusted EPS of $0.08 was in line with expectations. Keybanc maintained its price target of $28 (implying 93% upside), reiterating its long-term shareholder value expectations. The author contrasts this with Seadrill to highlight the market's tepid reaction to "in-line" results.
  • Amazon.com, Inc. (AMZN): Loop raised its price target, but the stock fell 4.3%. The target was raised from $360 to $405 (implying 54% upside), arguing that the inflection point for AWS revenue is still early, citing Anthropic, OpenAI, and Bedrock as evidence of demand; it also noted that the historical relationship between capital expenditure and incremental revenue (a lag of approximately six quarters) will continue. If this holds, Loop estimates AWS revenue will exceed consensus by $6 billion in the second half of 2026 and by $29 billion in 2027.
  • Precigen, Inc. (PGEN) and Broadcom Inc. (AVGO): Fell 15.6% and 8.1%, respectively. The report states the declines occurred "on limited news"; AVGO pulled back to its 100-day moving average.

How the Manager Views the Market

Stance [Cautious Neutral]. The report does not make a definitive judgment on the macro market but conveys a core view through individual stock cases: The market gives positive feedback to companies that beat expectations and raise guidance (e.g., Seadrill), while reacting weakly to companies that merely meet expectations (e.g., QXO), highlighting investors' high sensitivity to growth prospects in the current environment. The report does not disclose position structure data such as net exposure, leverage, or long/short ratios.

Position Moves: Where to Add, Where to Reduce

The report does not disclose any new positions, additions, reductions, or liquidations. All discussion revolves around the performance and market reaction of existing holdings, with no information on capital movement at the sector, theme, or geographic level.